Emcure Pharmaceuticals Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7afo7n20vjsr3xl3hbaj3kyd.pdf

Key Takeaways


The Mix Story: Gross Margins, Sanofi & ARV

Satish Mehta: "We hope to keep reporting stronger and better numbers as we go along year after year, and we would also like you to judge Emcure performance on an annual basis rather than every quarter."

Domestic Engine: Women's Health, Cardio & New Platforms

Namita Thapar: "57% women are anaemic and 30% men are anaemic. So, there is a huge potential in terms of just people who are not aware that they need it... it will be a two-pronged strategy of whatever is big, make it bigger and then also have some exciting new launches in these progressive markets."

International: Differentiated Products Driving the Next Leg


Pipeline & R&D: Complex Injectables, Biosimilars & ADC

Samit Mehta: "I think, at least initially, it will be a very low-risk strategy in terms of choosing an antibody and a payload, which is already tested, which is why I said the IP will come through the linker and also in terms of payload, most of the people are using derivatives of certain approved molecules."

Financial Framework: Margins, Cash Flow & Balance Sheet

Satish Mehta: "I am a strong believer on execution because everyone has strategies but the key to success is execution and also the focus will be on improving our profitability."

Guidance & Commitments

CommitmentSpecificsTimeline
Top-line growth13% to 14% (hopefully at the higher end)FY26
EBITDA margin improvement~150 bps expansion to ~20–21%FY26
Domestic growth200 bps above industry (low double digits)FY26
International growthMid-teensFY26
Europe growthHigh single digitsFY26
Canada growthTeensFY26
Emerging markets growth~20%, driven by non-ARVFY26
Debt-freeZero debtBy end of FY26
Capex~₹350 cr (±₹25–50 cr)FY26
Working capital days98–100 daysFY26
Bevacizumab launchForay into ophthalmic segmentFY26
Sanofi portfolio growthStrong growth expected from Q1 FY26, restructuring completeQ1 FY26 onward
Emcutix pipeline6 more SKUsNext 12 months
HIV contributionExpected to come down significantlyOver 3–4 years

Key Metrics

MetricQ4 FY25
Revenue from operations₹2,116 cr, +19.5% YoY
Domestic revenue₹929 cr, +25% YoY
International revenue₹1,187 cr, +16% YoY
Organic domestic growth (ex-Sanofi)10% YoY; 12% excluding FCM impact
Gross margin57.8%, down from 62.1% in Q4 FY24
EBITDA (ex-other income)₹390 cr, +25.2% YoY
EBITDA margin (ex-other income)18.4%, supported by operating leverage and productivity gains
Profit after tax₹197 cr, +63% YoY
ROW revenue₹481 cr, +39% YoY
Canada revenue₹310 cr, +6.1% YoY; sequential dip from ₹352 cr due to preponed bookings in Q3
Europe revenue₹396 cr, +2% YoY
PCPM6.3, up from 6.1 in Q3 FY25 and 5.4 in Q4 FY24
Net debt₹488 cr, reduced from ₹1,558 cr in FY24
Working capital days~98 days, stable
FY26 revenue growth guidance13% to 14%
FY26 EBITDA margin improvement guidance~150 bps over FY25, full year